



**Sangamo BioSciences, Inc.**  
Point Richmond Tech Center  
501 Canal Blvd., Suite A100  
Richmond, CA 94804  
510-970-6000 • 510-236-8951(Fax)

---

**For Immediate Release**

**SANGAMO BIOSCIENCES ANNOUNCES AGREEMENT WITH WYETH-  
AYERST LABORATORIES**

**Richmond, California** – January 15, 2002 - Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced that it has signed a collaborative research agreement with Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation (NYSE: AHP). Under the terms of this agreement, Sangamo will provide gene specific zinc finger DNA binding proteins, or ZFPs, to Wyeth-Ayerst for use in its internal research programs.

“More than 20 pharmaceutical and biotechnology companies have entered into agreements with Sangamo to use our Universal GeneTools™ ZFP technology platform for applications in pharmaceutical research,” said Edward Lanphier, Sangamo’s president and chief executive officer. “These include collaborations focused on drug target validation, small molecule drug screening and model systems development.”

As the human genome is deciphered, the need to understand the role that individual genes play in various diseases has increased dramatically. Sangamo’s Universal GeneTools™ are customized transcription factors designed to meet this growing need. Transcription factors are naturally occurring proteins that are found in virtually all organisms. By recognizing and binding to specific DNA sequences, they are able to turn genes "on" or "off." Sangamo engineers a specific kind of transcription factor called zinc finger DNA binding proteins (ZFPs), to selectively bind to and regulate virtually any gene of interest.

**About Sangamo**

Sangamo BioSciences, Inc. is focused on the research and development of novel transcription factors for the regulation of gene expression. The company’s most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Other therapeutics development programs are focused on cancer and infectious diseases. Sangamo’s Universal Gene Recognition™ technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company intends to establish Universal Gene Recognition™ as a widely used technology for commercial applications in human therapeutics, pharmaceutical discovery, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs.

*This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and Sangamo’s ZFP TF technology*



**Sangamo BioSciences, Inc.**  
Point Richmond Tech Center  
501 Canal Blvd., Suite A100  
Richmond, CA 94804  
510-970-6000 • 510-236-8951(Fax)

---

*platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, our ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.*

Contact: Edward Lanphier  
510 970 6000, ext. 207